bio-protocol Preprint

Not Peer Reviewed
Ask a question online

In vivo efficacy study

CVP Chad V. Pecot AVK Alexander V. Kabanov NV Natasha Vinod

Updated date: Jul 17, 2020

An abbreviated version of this protocol was published in Science Advances in Jun 2020

High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive metastatic model of lung adenocarcinoma

DOI: 10.1126/sciadv.aba5542

Related files

W Protocol - In vivo efficacy study.docx

How to cite:（Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used）

1. Pecot, C. V., Kabanov, A. V. and Vinod, N. (2020). In vivo efficacy study. Bio-protocol Preprint. bio-protocol.org/prep401.
2. Vinod, N., Hwang, D., Azam, S. H., Swearingen, A. E. D. V., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V. and Kabanov, A. V. (2020). High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive metastatic model of lung adenocarcinoma . Science Advances 6(25). DOI: 10.1126/sciadv.aba5542

Copyright: Content may be subjected to copyright.